Advertisement

Person › Details
Eric Ducournau (Pierre Fabre S.A.)
Ducournau, Eric (Pierre Fabre 201807– CEO before CEO of Pierre Fabre Dermo-Cosmetics joined 2000)
![]() |
Organisation | Pierre Fabre S.A. |
Group | Pierre Fabre (Group) | |
![]() |
Product | pharmaceutical |
Product 2 | cosmetics | |
Record changed: 2023-04-05 |
Advertisement

More documents for Eric Ducournau
- [1] Scorpion Therapeutics, Inc.. (4/4/23). "Press Release: Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer". Bost...
- [2] Atara Biotherapeutics, Inc.. (12/19/22). "Press Release: Atara Biotherapeutics’ Ebvallo (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD". Thousand Oaks, CA & Castres....
- [3] Urovant Sciences. (7/5/22). "Press Release: Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland". Basel &...
- [4] Atara Biotherapeutics, Inc.. (10/4/21). "Press Release: Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel)". South San Francisco, CA & Castres....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top